Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128781 | 0.90 | CA1 (0.61) | SMN1; SMN2HPGDNPC1RAB9AKMT2A | |
| SCHEMBL29431885 | 0.90 | CA1 (0.61) | SMN1; SMN2HPGDNPC1RAB9AKMT2A | |
| SCHEMBL343211 | 0.89 | CA1 (0.67) | HPGDNPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL865333 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2HPGDNPC1RAB9AKMT2A | |
| Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL29709382 | 0.81 | CA1 (0.72) | SMN1; SMN2HPGDNPC1RAB9AKMT2A | |
| Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL643758 | 0.81 | CA1 (0.72) | SMN1; SMN2HPGDNPC1RAB9AKMT2A | |
| SCHEMBL1478993 | 0.81 | CA12 (0.59) | SMN1; SMN2HPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL344841 | 0.80 | KDM4E (0.64) | HPGDKMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL31364552 | 0.80 | KDM4E (0.64) | HPGDKMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL7030719 | 0.79 | KMT2A (0.60) | SMN1; SMN2HPGDNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654642-B | Glycan analysis of proteins and cells | MUSC研究发展基金会 | 2023-04-28 | — | — | CN | disclosed |
| US-20210208156-A1 | GLYCAN ANALYSIS OF PROTEINS AND CELLS | VAN ANDEL RESEARCH INSTITUTE | 2021-07-08 | — | — | US | disclosed |
| EP-3802624-A1 | GLYCAN ANALYSIS OF PROTEINS AND CELLS | Musc Foundation for Research Development (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-112654642-A | Glycan analysis of proteins and cells | MUSC研究发展基金会 | 2021-04-13 | — | — | CN | disclosed |
| US-20200255518-A1 | ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE | LFB USA, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-2388273-B1 | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use | LFB USA INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170002095-A1 | CANCER SPECIFIC GLYCANS AND USE THEREOF | GLYKOS FINLAND OY (FI) | 2017-01-05 | — | — | US | disclosed |
| US-9410126-B2 | Carbohydrate profile compositions from human cells and methods for analysis and modification thereof | GLYKOS FINLAND OY (FI) | 2016-08-09 | — | — | US | disclosed |
| WO-2016036705-A1 | GLYCAN PANELS AS SPECIFIC TUMOR TISSUE BIOMARKERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20150140576-A1 | CANCER SPECIFIC GLYCANS AND USE THEREOF | GLYKOS FINLAND OY (FI) | 2015-05-21 | — | — | US | disclosed |
| US-20080118501-A1 | Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use | GTC BIOTHERAPEUTICS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1913385-A2 | TISSUE CARBOHYDRATE COMPOSITIONS AND ANALYSIS THEREOF | Glykos Finland Oy (FI) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910838-A2 | CANCER SPECIFIC GLYCANS AND USE THEREOF | Glykos Finland Oy (FI) | 2008-04-16 | — | — | EP | disclosed |
| EP-1904532-A2 | NOVEL CARBOHYDRATE PROFILE COMPOSITIONS FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF | SUOMEN PUNAINEN RISTI VERIPALVELU (FI) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007054622-A1 | NOVEL CARBOHYDRATE PROFILE COMPOSITIONS FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF | SUOMEN PUNAINEN RISTI, VERIPALVELU (FI) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007054621-A1 | TISSUE CARBOHYDRATE COMPOSITIONS AND ANALYSIS THEREOF | GLYKOS FINLAND OY (FI) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007048077-A2 | ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE | GTC BIOTHERAPEUTICS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007012695-A2 | TISSUE CARBOHYDRATE COMPOSITIONS AND ANALYSIS THEREOF | GLYKOS FINLAND OY (FI) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007010089-A2 | CANCER SPECIFIC GLYCANS AND USE THEREOF | GLYKOS FINLAND OY (FI) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007006870-A2 | NOVEL CARBOHYDRATE PROFILE COMPOSITIONS FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF | SUOMEN PUNAINEN RISTI, VERIPALVELU (FI) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150140576-A1 | CANCER SPECIFIC GLYCANS AND USE THEREOF | SIGLEC7, FUT5, SIGLEC9 | SMN1; SMN2 4793/4885HPGD 2666/4885NPC1 1788/4885 |
| US-20170002095-A1 | CANCER SPECIFIC GLYCANS AND USE THEREOF | SIGLEC7, FUT5, SIGLEC9 | SMN1; SMN2 4793/4885HPGD 2666/4885NPC1 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.